via Harvard University
A novel gene-editing experiment seems to have permanently reduced LDL and triglyceride levels in monkeys.
What if a single injection could lower blood levels of cholesterol and triglycerides — for a lifetime?
In the first gene-editing experiment of its kind, scientists have disabled two genes in monkeys that raise the risk for heart disease. Humans carry the genes as well, and the experiment has raised hopes that a leading killer may one day be tamed.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cure for heart disease
- The heart of the matter: Heartworm disease in dogs
Immature heartworms enter through the skin when an infected mosquito bites the dog. These immature worms grow to adulthood, mate and produce offspring inside the dog, disturbing normal blood flow and ...
- Irregular bone marrow cells may increase heart disease risk
Over time, bone marrow stem cells develop key genetic errors and pass them on to immune cells. This may increase the risk of developing heart disease.
- Anxiety and Depression Treatments Have Significant Impact on Heart Disease Outcomes
A study was conducted to determine the effect of anxiety or depression treatments on clinical outcomes following hospitalization for ischemic disorders and heart failure.
- Study: Women with heart disease prescribed cholesterol-lowering drugs less often than men
Women with heart disease may be prescribed cholesterol-reducing statins less frequently than men, contravening recommended treatment guidelines, according to new research released Thursday.
- Women with heart disease are less likely to receive life-saving drugs than men, researchers find
Women with heart disease are less often treated with cholesterol-lowering drugs than men, according to research presented today at ESC Preventive Cardiology 2024, a scientific congress of the European ...
Go deeper with Google Headlines on:
Cure for heart disease
[google_news title=”” keyword=”cure for heart disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Gene editing
- Regeneron and Mammoth team up to develop gene editing therapies
Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.
- Regeneron inks $100M deal to develop gene-editing therapies
Tarrytown-based Regeneron Pharmaceuticals has struck a $100 million deal with Mammoth Biosciences, a California-based biotechnology company, to develop and commercialize gene editing therapies for ...
- This AI Just Designed a More Precise CRISPR Gene Editor for Human Cells From Scratch
Based on large language models—the tech behind the popular ChatGPT—Profluent's AI designed a new gene editor and put it to work in human cells.
- Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration
Regeneron Pharmaceuticals will use Mammoth Biosciences’ CRISPR-based ultracompact gene editing platform to develop in vivo therapies for tissues and cell types beyond the liver.
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
Go deeper with Google Headlines on:
Gene editing
[google_news title=”” keyword=”gene editing” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
